Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BEIGF Beigene Ltd (PK)

0.00 (0.00%)
Jun 14 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0.00
Bid Price 10.00
Ask Price 15.00
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Beigene Ltd (PK) BEIGF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 12.58 16:02:43
Open Price Low Price High Price Close Price Prev Close
12.58 12.58
Trades Volume Avg Volume 52 Week Range
0 0.00 - 11.00 - 16.78
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 12.58 USD

Beigene Ltd (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
15.62B 1.01B - 2.46B -881.71M -0.71 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Beigene (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No BEIGF Message Board. Create One! See More Posts on BEIGF Message Board See More Message Board Posts

Historical BEIGF Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months11.2812.5811.0012.153681.3011.52%
6 Months11.2812.5811.0012.153681.3011.52%
1 Year16.7816.7811.0014.31850-4.20-25.03%
3 Years25.375529.254111.0025.9842,170-12.80-50.42%
5 Years20.173629.254111.0025.9439,977-7.59-37.64%

Beigene (PK) Description

We are a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Our internally-developed lead drug candidates are currently in late-stage clinical trials, including 21 registration or registration-enabling trials in 14 discrete cancer indications. We have submitted three new drug applications for regulatory approval in China and are planning for new drug launches and additional submissions in China and the United States in 2019 and 2020. In addition, we are marketing three in-licensed cancer drugs in China from which we have been generating product revenue since September 2017. We started as a research and development company in Beijing in 2010, focusing on developing best-in-class oncology drugs. Over the last nine years, we have developed into a fully-integrated global biotechnology company with operations in China, the United States, Europe and Australia, including a more than 800-person global clinical development team running over 50 ongoing or planned clinical trials as of January 24, 2019. We also have a growing commercial team that is selling our existing in-licensed drugs in China and preparing for launches of our internally-developed drug candidates in China and the United States, as well as internal manufacturing capabilities in China that are operational or under construction for the clinical and commercial supply of our small molecule and biologic drug candidates.

Your Recent History

Delayed Upgrade Clock